Paula Wittler Joins PetVivo Holdings, Inc. as the Western Business Development Manager
PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) has appointed Paula Wittler as the new Business Development Manager for the Western Region. Wittler brings over 25 years of experience in veterinary product management and marketing, previously working with Zoetis Animal Health. CEO John Lai emphasized her role in promoting Spryng™, a veterinary medical device designed to improve the treatment of lameness and joint issues in companion animals. PetVivo continues to focus on innovative biomedical devices and has a robust product pipeline, furthering its mission in animal health.
- Appointment of Paula Wittler enhances sales and distribution capabilities.
- Wittler's extensive experience in veterinary products could accelerate market penetration.
- Spryng™ addresses the root cause of joint afflictions, potentially improving animal health outcomes.
- None.
MINNEAPOLIS, MN, US, Sept. 07, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Paula Wittler has accepted a position with the Company as its new Business Development Manager for the Western Region of the United States.
"We are incredibly excited to add Paula to our sales and distribution team,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc. “The experience Paula brings to PetVivo is extraordinarily valuable to our efforts in introducing our innovative product Spryng™ with OsteoCushion™ technology to veterinarians throughout the United States”
Paula Wittler has more than 25 years of experience related to management, marketing and distribution of veterinary products in the United States. She has served in various roles in product promotion, product distribution, technical sales and marketing with veterinary companies such as Zoetis Animal Health (f/k/a Pfizer Animal Health). Paula is a graduate of UC Santa Barbara. When not working, Paula tries to spend as much time in the saddle as possible. She competes/shows her Non-Pro Bridle horse in the National Reined Cow Horse Association, as well as owns an Open Derby Horse being trained and shown by a professional trainer.
“Joining PetVivo as a new Business Development Manager is an incredible opportunity for me to continue my passion, leverage my industry knowledge, and positively impact the quality of life for horses and companion animals. I am humbled and honored to be a part of this valuable team,” said Paula Wittler. “I am thankful for the opportunity to be able to promote and sell a veterinary medical device that addresses the affliction (i.e. lost or damaged cartilage) rather than simply treating the symptoms (e.g. pain and inflammation). I truly believe Spryng has the ability to improve the medical outcomes of animals suffering from lameness and other joint related afflictions, such as osteoarthritis, thereby enhancing the lives of animals and their owners.”
For more information about PetVivo Holdings, Inc. and its innovative product, Spryng, please contact info1@petvivo.com or visit https://petvivo.com/ and https://sprynghealth.com/.
About PetVivo Holdings, Inc.
PetVivo Holdings Inc. (NASDAQ: PETV & PETVW) is an emerging biomedical device company currently focused on the manufacturing, commercialization and licensing of innovative medical devices and therapeutics for companion animals. The Company's strategy is to leverage human therapies for the treatment of companion animals in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than more stringently regulated pharmaceuticals and biologics.
PetVivo has a pipeline of seventeen products for the treatment of animals and people. A portfolio of nineteen patents protects the Company's biomaterials, products, production processes and methods of use. The Company’s lead product SPRYNG, a veterinarian-administered, intraarticular injection for the treatment of lameness and other joint related afflictions, including osteoarthritis, in dogs and horses, is currently available for commercial sale to veterinarians.
CONTACT:
John Lai, CEO
PetVivo Holdings, Inc.
Email: info1@petvivo.com
(952) 405-6216
Forward-Looking commercial Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation the Company’s proposed development and commercial timelines, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements, including the potential listing of the Company’s common stock on Nasdaq, are based on information currently available the Company and its current plans or expectations and are subject to a number of uncertainties and risks that could significantly affect current plans. Risks concerning the Company’s business are described in detail in the Company’s Annual Report on Form 10-K for the year ended March 31, 2022 and other periodic and current reports filed with the Securities and Exchange Commission. The Company is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Attachment
FAQ
Who is the new Business Development Manager at PetVivo Holdings?
What is Spryng™ offered by PetVivo?
How does PetVivo Holdings plan to enhance animal health?
What experience does Paula Wittler bring to PetVivo Holdings?
What is the stock symbol for PetVivo Holdings?
